Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T
cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy …

Lung carcinoma is one of the most common cancers and has one of the lowest survival rates
in the world. Cytokines such as interleukin-12 (IL-12) have demonstrated considerable …

Cancer immunotherapies, including adoptive T cell transfer, can be ineffective because
tumors evolve to display antigen-loss-variant clones. Therapies that activate multiple …

Pancreatic and colorectal cancers are often KRAS mutated and are incurable when tumor
DNA or protein persists or recurs after curative intent therapy. Cancer vaccine ELI-002 2P …

Therapeutic cancer vaccines have undergone a resurgence in the past decade. A better
understanding of the breadth of tumour-associated antigens, the native immune response …

The often immune-suppressive tumor microenvironment (TME) may hinder immune evasion
and response to checkpoint blockade therapies. Pharmacological activation of the STING …

Chimeric antigen receptor (CAR) T cell therapy effectively treats human cancer, but the loss
of the antigen recognized by the CAR poses a major obstacle. We found that in vivo vaccine …

Within the past decade, the field of immunotherapy has revolutionized the treatment of many
cancers with the development and regulatory approval of various immune-checkpoint …

Develo** strategies to inflame tumors is critical for increasing response to immunotherapy.
Here, we report that low-dose radiotherapy (LDRT) of murine tumors promotes T-cell …